- CONDITION CENTERS
Dr. LaFleur is a research assistant professor in the department of pharmacotherapy, University of Utah College of Pharmacy Pharmacotherapy Outcomes Research Center.
Nearly one third of women who develop cancer in the United States have breast cancer.1 Should this cancer metastasize, most will eventually have bone involvement.2 Thus, intravenous (IV) bisphosphonates like pamidronate and zoledronate have had a large role in breast cancer, as they treat bone metastases and bone pain.2,3 Now, clinicians also are using bisphosphonates in these patients for a disease that is more familiar to most pharmacists— osteoporosis. Pharmacists need to understand breast cancer patients' risks for osteoporosis and recommend appropriate screening and treatment.
Breast cancer treatment increases osteoporosis risk in 2 ways. One cause is development of chemotherapyinduced amenorrhea in premenopausal women.4 Most patients treated with a common regimen (cyclophosphamide, methotrexate, and fluorouracil) for estrogen- receptor?positive (ER+) or negative breast cancer developed amenorrhea.4 These women have rapid and sustained bone loss.5 A second cause exists only in women with ER+ cancers. In these women, tamoxifen, which has been the gold standard for adjuvant endocrine therapy for more than 2 decades, is now being replaced by aromatase inhibitors (anastrazole, letrozole, examestane), which do not protect patients against osteoporosis as well as tamoxifen. In fact, their estrogen-suppressing effects actually increase the risk.6-8 Aromatase inhibitors reduce cancer recurrence by as much as an additional 30% over tamoxifen.9,10 Their risk of serious adverse events like ischemic stroke, endometrial cancer, and venous thromboembolism is lower.6
The American Society of Clinical Oncology (ASCO) recently issued a new guideline for osteoporosis screening and treatment in breast cancer.3 It stresses the need for oncology clinicians to expand their roles to evaluating bone health routinely and regularly.3 The breast cancer?specific guideline was based on a more general osteoporosis guideline produced by the US Preventive Services Task Force (USPSTF).11 The USPSTF recommends routine bone mineral density (BMD) screening in women at high risk for osteoporosis. The USPSTF considers certain women at high risk—those older than age 65, or between 60 and 64 and having other risk factors like a family history of osteoporosis, or those with a low body weight (<154 lb) or a prior fragility fracture. For breast cancer patients, ASCO adds 2 more high-risk categories: (1) postmenopausal women (of any age) receiving aromatase inhibitors, and (2) younger women with chemotherapy-associated premature menopause.
The Figure shows the ASCO algorithm for recommending BMD screening, lifestyle changes, and treatment interventions in women with and without these high-risk designations. Like the USPSTF, ASCO states that clinicians should encourage all patients to undertake preventive measures. First, eating a healthy diet supplemented with calcium and vitamin D maintains adequate calcium to continually rebuild bone. Second, regular exercise strengthens bone and maintains high bone density, and, third, smoking avoidance helps prevent premature bone loss. These measures are recommended to all patients. High-risk patients should also receive BMD scans every year, and patients with BMD T-scores at or below the threshold for osteoporosis (-2.5) should receive treatment.
ASCO = American Society of Clinical Oncology; BMD = bone mineral density.
A few of the agents approved by the FDA for osteoporosis prevention and treatment require special consideration in women with breast cancer. Raloxifene should be avoided in women who have had 5 years of treatment with tamoxifen because of concerns about higher cancer recurrence and mortality rates.3,12 Teriparatide also is not recommended, because it caused osteosarcoma in animals.3,13 Estrogen plus progestin is no longer recommended for osteoporosis prevention because of the increased risk for serious life-threatening adverse events, including breast cancer.3,14 Generally, due to strong safety profiles and a larger pool of evidence supporting their benefits, bisphosphonates are the treatment of choice in patients with and without breast cancer.3
As in many symptomless chronic diseases, patient adherence and persistence with osteoporosis treatment are poor. A recent meta-analysis showed that only about half of patients persist with bisphosphonates more than 6 months, and most discontinue after the first month.15 Poor adherence is alarming; increasing evidence shows that patients need at least 6 months exposure to reap treatment benefits.16 The newer oral bisphosphonates' longer dosing intervals may improve patient adherence.17 For patients who have difficulty persisting with oral bisphosphonates, even with longer dosing intervals, the once-yearly bisphosphonate zoledronate may be an alternative.18 Zoledronate lacks the oral bisphosphonates' administration restrictions but must be infused intravenously; most physicians' offices are unable to infuse IV drugs. Additionally, a flu-like infusion reaction occurs after a first dose in about 16% of patients.
Because the risk of osteoporosis increases in patients with breast cancer, pharmacists need to be aware of the guidelines for preventing fractures, as well as counseling points for these patients.
GI = gastrointestinal.